search
Back to results

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

Primary Purpose

Pathological Gambling

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
olanzapine
sugar pill
Sponsored by
Lindner Center of HOPE
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pathological Gambling

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female outpatients aged 18- 75 years of age.
  2. Patients will have problematic gambling behavior of at least 6 months duration that meets the DSM-IV definition of pathological gambling and a South Oaks Gambling Screen Score greater than 5.
  3. All patients will have a complete medical and psychiatric history, physical examination, laboratories, and ECG before study entry.
  4. Baseline laboratory values and ECG must be normal, or abnormalities must be clinically insignificant.
  5. Patients will not have received any psychotropic medication for at least one week prior to the first study visit.

Exclusion Criteria:

  1. Patients who have any significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination.
  2. Patients who are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit).
  3. Patients who have ever had psychotic symptoms, who have ever met DSM-IV criteria for a manic episode (i.e., have bipolar I disorder), or who have met criteria for DSM-IV psychoactive substance dependence in the past 1 month.
  4. Patients who meet DSM-IV criteria for antisocial or borderline personality disorder.
  5. Patients who use any medications which, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with olanzapine. For example, patients taking diet pills or stimulants will not be enrolled.
  6. Patients who have taken any psychiatric medication within 7 days prior to the screening assessment.
  7. Patients who have a history of hypersensitivity to olanzapine.
  8. Patients who display clinically significant suicidal ideation.
  9. Patients who have recently (within the past 3 months) begun any type of non-pharmacologic treatment for pathological gambling (including psychotherapy, behavior therapy, group therapy, or family therapy). This does not exclude participation in support groups (e.g., Gamblers Anonymous.) Patients who have been involved in long-standing psychological therapies (e.g., psychotherapy for at least the last 3 months) will be permitted to continue in that therapy provided that no new therapeutic technique or increase in frequency of psychotherapy occurs concurrent with the study.
  10. Patients who exhibit or suggest that they may display behavior that will not be conducive to the study procedures.

Sites / Locations

  • University of Cincinnati Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

olanzapine

sugar pill

Arm Description

active zyprexa (olanzapine)

Placebo (fake pill)

Outcomes

Primary Outcome Measures

Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS)

Secondary Outcome Measures

Full Information

First Posted
February 20, 2007
Last Updated
December 12, 2011
Sponsor
Lindner Center of HOPE
Collaborators
Eli Lilly and Company, University of Cincinnati
search

1. Study Identification

Unique Protocol Identification Number
NCT00438776
Brief Title
Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lindner Center of HOPE
Collaborators
Eli Lilly and Company, University of Cincinnati

4. Oversight

5. Study Description

Brief Summary
The purpose of this research study is to evaluate the efficacy (effectiveness) and safety of olanzapine in treating pathological gambling.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pathological Gambling

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
olanzapine
Arm Type
Active Comparator
Arm Description
active zyprexa (olanzapine)
Arm Title
sugar pill
Arm Type
Placebo Comparator
Arm Description
Placebo (fake pill)
Intervention Type
Drug
Intervention Name(s)
olanzapine
Other Intervention Name(s)
zyprexa
Intervention Description
2.5mg to 15mg daily
Intervention Type
Drug
Intervention Name(s)
sugar pill
Other Intervention Name(s)
fake pill
Intervention Description
matching placebo to olanzapine
Primary Outcome Measure Information:
Title
Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS)
Time Frame
per protocol

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female outpatients aged 18- 75 years of age. Patients will have problematic gambling behavior of at least 6 months duration that meets the DSM-IV definition of pathological gambling and a South Oaks Gambling Screen Score greater than 5. All patients will have a complete medical and psychiatric history, physical examination, laboratories, and ECG before study entry. Baseline laboratory values and ECG must be normal, or abnormalities must be clinically insignificant. Patients will not have received any psychotropic medication for at least one week prior to the first study visit. Exclusion Criteria: Patients who have any significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination. Patients who are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit). Patients who have ever had psychotic symptoms, who have ever met DSM-IV criteria for a manic episode (i.e., have bipolar I disorder), or who have met criteria for DSM-IV psychoactive substance dependence in the past 1 month. Patients who meet DSM-IV criteria for antisocial or borderline personality disorder. Patients who use any medications which, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with olanzapine. For example, patients taking diet pills or stimulants will not be enrolled. Patients who have taken any psychiatric medication within 7 days prior to the screening assessment. Patients who have a history of hypersensitivity to olanzapine. Patients who display clinically significant suicidal ideation. Patients who have recently (within the past 3 months) begun any type of non-pharmacologic treatment for pathological gambling (including psychotherapy, behavior therapy, group therapy, or family therapy). This does not exclude participation in support groups (e.g., Gamblers Anonymous.) Patients who have been involved in long-standing psychological therapies (e.g., psychotherapy for at least the last 3 months) will be permitted to continue in that therapy provided that no new therapeutic technique or increase in frequency of psychotherapy occurs concurrent with the study. Patients who exhibit or suggest that they may display behavior that will not be conducive to the study procedures.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan L McElroy, MD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0559
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18251624
Citation
McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008 Mar;69(3):433-40. doi: 10.4088/jcp.v69n0314.
Results Reference
result

Learn more about this trial

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

We'll reach out to this number within 24 hrs